GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » ROC (Joel Greenblatt) %

BriaCell Therapeutics (STU:8BT) ROC (Joel Greenblatt) % : -1,455.03% (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BriaCell Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. BriaCell Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -1,455.03%.

The historical rank and industry rank for BriaCell Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

STU:8BT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -350900   Med: -7371.13   Max: -5.71
Current: -841.45

During the past 13 years, BriaCell Therapeutics's highest ROC (Joel Greenblatt) % was -5.71%. The lowest was -350900.00%. And the median was -7371.13%.

STU:8BT's ROC (Joel Greenblatt) % is ranked worse than
64.35% of 1470 companies
in the Biotechnology industry
Industry Median: -338.875 vs STU:8BT: -841.45

BriaCell Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


BriaCell Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for BriaCell Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics ROC (Joel Greenblatt) % Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -7,369.27 -945.79

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -248.31 -915.00 -1,455.03

Competitive Comparison of BriaCell Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, BriaCell Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's ROC (Joel Greenblatt) % falls into.



BriaCell Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Oct. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.02 + 0 + 4.489) - (0.992 + 0 + 0)
=3.517

Working Capital(Q: Jan. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.028 + 0 + 5.018) - (3.602 + 0 + 0)
=1.444

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of BriaCell Therapeutics for the quarter that ended in Jan. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Jan. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2023  Q: Jan. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.092/( ( (0 + max(3.517, 0)) + (0 + max(1.444, 0)) )/ 2 )
=-36.092/( ( 3.517 + 1.444 )/ 2 )
=-36.092/2.4805
=-1,455.03 %

Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (STU:8BT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


BriaCell Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (STU:8BT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines